With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

The hairstylist and Netflix star has made a candid confession about his use of weight loss drugs to tackle problems with ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

PRNewswire/ -- (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today ...

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...